Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy
PINPOINT
Reducing Racial Disparities in Cancer Care With PINPOINT (Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy)
2 other identifiers
interventional
81
1 country
1
Brief Summary
The purpose of the research is to: develop an educational website to empower Black and African American cancer patients to make informed decisions about personalized cancer treatment and clinical trials. The sample size for the qualitative interviews was (n=48) when saturation was achieved. With a goal of (n=33) for the pilot trial, the overall target sample size for the study is (n=81).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 12, 2021
CompletedFirst Submitted
Initial submission to the registry
August 27, 2021
CompletedFirst Posted
Study publicly available on registry
September 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 19, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 19, 2023
CompletedAugust 11, 2025
August 1, 2025
1.9 years
August 27, 2021
August 5, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Community Advisory Board, Key Informants and Pilot Testers
Employ a community-engaged approach, including a Community Advisory Board and key informant interviews, to a) assess knowledge, attitudes, beliefs, and sociocultural, clinical, and system-level factors (e.g., barriers) that may explain disparities in decisions about use of precision oncology in Black cancer patients
June 2021-June 2022
Website Development
Utilize this information to guide the iterative development and pilot testing of an innovative, patient-centered and culturally tailored internet-based education and decision support intervention, "Promoting INformed approaches in Precision Oncology and ImmuNoTherapy (PINPOINT)," to reduce racial disparities in access to and use of guideline-based therapy.
June 2021-June 2023
Study Arms (1)
PINPOINT Digital Educational Tool
EXPERIMENTALNewly diagnosed Black cancer patients will be asked to access and engage with the educational website/intervention prototype before their clinic visit or in the clinic immediately before their appointment with their treating oncologist.
Interventions
The intervention prototype called the PINPOINT Digital Educational Tool will be comprised of four main sections that include information about: 1) precision oncology; 2) clinical trials; 3) "Learn More" screens; and 4) discussion points and questions for the treating clinician. The intervention prototype will also include a search function, short videos of patient testimonials, patient-provider interaction about immunotherapy and clinical trials, as well as a list of questions/concerns that the patient could print (or save electronically) and take with them to their provider visit. An optional chatbot will be available in the corner of the screen. Users can ask the chatbot questions about any of the material on the website or request additional information. The chatbot will also be able to help patients search for molecularly targeted and immunotherapy clinical trials and offer additional resources (such as websites and online support groups).
Eligibility Criteria
You may qualify if:
- Patient Key Informant:
- Age 18 and older
- Self-identify as Black/African American
- Diagnosed with solid tumor
- Able to read and speak English fluently
- Able to provide informed consent
- Able to complete 1 survey and an in-depth interview
- Relative Key Informant:
- Age 18 and older
- Spouse, blood relative, or caregiver of a cancer patient who identifies as Black/African American
- Able to read and speak English fluently
- Able to provide informed consent
- Able to complete 1 survey and an in-depth interview
- Provider Key Informant:
- Age 18 and older
- +13 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rutgers, The State University of New Jerseylead
- American Cancer Society, Inc.collaborator
- Pfizercollaborator
Study Sites (1)
The Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Anita Y Kinney, PhD, RN
Rutgers Cancer Institute
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Study Principal Investigator; Associate Director for Cancer Health Equity
Study Record Dates
First Submitted
August 27, 2021
First Posted
September 5, 2021
Study Start
July 12, 2021
Primary Completion
May 19, 2023
Study Completion
May 19, 2023
Last Updated
August 11, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share